Karus Therapeutics secures investment

Southampton, UK – 7 January 2009 – Innovative pharmaceutical company Karus Therapeutics Ltd has today announced the closing of a £0.9 million investment. Investors include IP Venture Fund, Esperante, Drummond Paris and a number of Business Angels. The investment will be used to advance the development of new drugs to treat cancer and inflammatory diseases […]

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Prog Med Chem. 2009, 48, p81-131.